Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Next Previous
Trial Profile

A Phase 1b/2 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Timdarpacept (Primary)
  • Indications Carcinoma; Cervical cancer; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Head and neck cancer; Hodgkin's disease; Liver cancer; Lymphoma; Malignant melanoma; Marginal zone B-cell lymphoma; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; T-cell lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors ImmuneOnco Biopharma

Most Recent Events

  • 04 Jun 2024 Results (As of 28 Dec 2023, n= 33 ) in patients with R/R classical Hodgkin lymphoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 12 Dec 2023 Results (As of 19 Jul 2023, n=20 ) assessing anti-tumor effectivity and safety in classical Hodgkin Lymphoma patients, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 06 Jun 2023 Results (n=14) assessing safety and efficacy of IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top